| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
65,540,000 |
| Market
Cap: |
4.24(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.84 - $64.7 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 18.1 |
| Insider 3/6 Months : 18.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Co.'s ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Co.'s primary oncology program is ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
750,000 |
750,000 |
750,000 |
| Total Buy Value |
$0 |
$9,375,000 |
$9,375,000 |
$9,375,000 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
19 |
3,569,526 |
3,587,529 |
3,587,529 |
| Total Sell Value |
$1,227 |
$66,624,154 |
$66,912,708 |
$66,912,708 |
| Total People Sold |
1 |
5 |
5 |
5 |
| Total Sell Transactions |
1 |
23 |
24 |
24 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Venkatesan Jay |
Director |
– • • |
2020-12-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(993,801) |
3,000,980 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
260,528 |
321,162 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2020-12-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(993,801) |
3,000,980 |
|
- |
|
| Conway Robert |
Director |
– • – |
2020-11-19 |
4 |
B |
$8.03 |
$80,300 |
I/I |
10,000 |
25,000 |
2.1 |
32% |
|
| Rickey James Paul |
Senior VP and CFO |
• – – |
2020-06-30 |
4 |
D |
$9.71 |
$21,925 |
D/D |
(2,258) |
26,285 |
|
- |
|
| Peng Stanford L |
See Remarks |
• – – |
2020-06-30 |
4 |
D |
$9.71 |
$38,092 |
D/D |
(3,923) |
28,294 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2020-06-30 |
4 |
D |
$9.71 |
$79,884 |
D/D |
(8,227) |
60,634 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
67,569 |
68,861 |
|
- |
|
| Peng Stanford L |
President & Head of R&D |
• – – |
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
32,217 |
32,217 |
|
- |
|
| Rickey James Paul |
Senior VP and CFO |
• – – |
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
18,543 |
28,543 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2019-12-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
1,292 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2019-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
6,292 |
|
- |
|
| Rickey James Paul |
Senior VP and CFO |
• – – |
2019-05-30 |
4 |
B |
$4.95 |
$49,500 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Tiger Management L.l.c. |
10% Owner |
– – • |
2019-02-08 |
4 |
S |
$5.85 |
$146,245 |
I/I |
(25,000) |
137,728 |
|
- |
|
| Thompson Peter A |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
I/I |
372,439 |
3,670,955 |
2.25 |
- |
|
| Cui Xiangmin |
Director |
– • • |
2019-01-18 |
4 |
A |
$5.37 |
$16,999,997 |
I/I |
3,165,735 |
3,165,735 |
|
- |
|
| Orbimed Capital Gp Vi Llc |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
I/I |
372,439 |
3,670,955 |
2.25 |
- |
|
| Heron Patrick J |
10% Owner |
– – • |
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
D/D |
372,439 |
2,571,450 |
2.45 |
- |
|
| Topper James N |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
I/I |
372,439 |
2,571,450 |
2.25 |
- |
|
| Venkatesan Jay |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,024,999 |
I/I |
190,875 |
3,994,781 |
2.25 |
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,024,999 |
I/I |
190,875 |
3,994,781 |
2.64 |
- |
|
| Alpine Bioventures Gp, Llc |
10% Owner |
– – • |
2019-01-18 |
4 |
B |
$5.37 |
$1,024,999 |
D/D |
190,875 |
3,994,781 |
2.45 |
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2018-05-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
11,292 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2018-05-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
17,292 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2018-05-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
20,292 |
|
- |
|
183 Records found
|
|
Page 5 of 8 |
|
|
0.04 (0.06%) 
